Michelle Morgan
Michelle Morgan serves as Associate Director for TRxA, overseeing the program’s operations and project management. When joining C-Path in 2018, she was responsible for several initiatives within C-Path’s Translational and Safety Science Program, including facilitating working groups of the Predictive Safety Testing Consortium that focused on identifying novel drug development tools that enable safety testing in the areas of nephrotoxicity, testicular toxicity and vascular injury. She also managed activities of C-Path’s Biomarker Data Repository (BmDR) and Acute Kidney Injury Project. Prior to joining C-Path, Michelle served nearly 30 years with the Muscular Dystrophy Association, including her leadership role overseeing strategic development and implementation of the organization’s nationwide health care and support services programs for individuals living with neuromuscular diseases.
